NxStage Medical Inc. (NXTM) is Trading Lower on Unusual Volume for February 10

Equities Staff |

NxStage Medical Inc. (NXTM) experienced unusually high volume on Feb. 10, as the stock lost 13.98% to a closing price of $15.20. The stock saw 1.83 million shares trade hands over the course of the day on 10,278 trades. Given that the stock’s average daily volume over the last month has been 567,137 shares a day, this represents a pretty substantial spike over the norm.

NxStage Medical Inc. has a P/B ratio of 5.12. The stock has traded between $22.60 and $13.47 over the last 52-weeks, its 50-day SMA is now $19.87, and its 200-day SMA $17.39.

NxStage Medical Inc is a medical device company. The Company develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures.

Headquartered in Lawrence, MA, NxStage Medical Inc. has 3,400 employees and is currently under the leadership of CEO Jeffrey H. Burbank.

For a complete fundamental analysis analysis of NxStage Medical Inc., check out Equities.com’s Stock Valuation Analysis report for NXTM. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.


The Russell 3000 is not well known outside the world of finance, but it’s one of the strongest indices out there for getting a broad sense of the stock market. Unlike the better-known Dow Jones Industrial Average or S&P 500, membership on the Russell 3000 isn’t selected by committee. It’s simply the 3,000 most valuable companies in the country.

With 3,000 stocks making up the index, it gives a broad look at the markets, including the small-and mid-cap companies that aren’t on the Dow or the S&P 500. And with a rules-based system for determining membership, there’s no bias that could potentially limit membership. That’s why many financial professionals will turn to the Russell 3000 long before the better-known indices when trying to take the temperature of the market.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets


The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…


Wealthfront is an automated investment service that serves as an alternative to traditional financial advisory services. The company manages a diversified, continually rebalanced portfolio of index funds on their clients’…